Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDMO NASDAQ:MLTX NASDAQ:MTSR NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDMOAvid Bioservices$12.50+0.1%$12.50$8.74▼$12.51$799.18M1.391.45 million shs3.07 million shsMLTXMoonLake Immunotherapeutics$59.50+1.6%$52.40$31.42▼$61.87$3.58B1.27375,346 shs1.03 million shsMTSRMetsera$35.66-1.5%$34.43$12.30▼$47.40$3.71BN/A1.28 million shs1.81 million shsVKTXViking Therapeutics$26.83-2.4%$31.24$18.92▼$81.73$3.04B0.739.63 million shs4.82 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDMOAvid Bioservices0.00%0.00%0.00%0.00%+28.42%MLTXMoonLake Immunotherapeutics+1.61%+7.36%+11.59%+21.85%+28.48%MTSRMetsera-1.52%+1.83%+3.54%+24.38%+3,565,999,900.00%VKTXViking Therapeutics-2.40%+0.79%-21.04%-0.78%-54.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDMOAvid Bioservices0.7798 of 5 stars1.00.00.04.50.61.70.6MLTXMoonLake Immunotherapeutics2.2739 of 5 stars3.42.00.00.02.42.50.0MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/AVKTXViking Therapeutics4.2605 of 5 stars3.52.00.04.73.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideMLTXMoonLake Immunotherapeutics 2.78Moderate Buy$74.4325.09% UpsideMTSRMetsera 3.00Buy$59.0065.45% UpsideVKTXViking Therapeutics 3.00Buy$86.92223.98% UpsideCurrent Analyst Ratings BreakdownLatest CDMO, MLTX, MTSR, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025MTSRMetseraCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight8/28/2025MTSRMetseraBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $50.008/19/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.008/6/2025MLTXMoonLake ImmunotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$74.00 ➝ $82.007/28/2025MLTXMoonLake ImmunotherapeuticsRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold7/28/2025MLTXMoonLake ImmunotherapeuticsRothschild & Co RedburnSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$65.007/24/2025VKTXViking TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetStrong-Buy ➝ Strong-Buy$125.00 ➝ $122.007/24/2025VKTXViking TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$31.00 ➝ $38.006/25/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.006/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.006/10/2025MTSRMetseraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $62.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$5.57 per shareN/AMTSRMetseraN/AN/AN/AN/A$4.28 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$7.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/AVKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest CDMO, MLTX, MTSR, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/A7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/A7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDMOAvid BioservicesN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDMOAvid Bioservices3.581.300.92MLTXMoonLake Immunotherapeutics0.2116.6516.65MTSRMetseraN/A5.265.26VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDMOAvid Bioservices97.16%MLTXMoonLake Immunotherapeutics93.85%MTSRMetseraN/AVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCDMOAvid Bioservices3.05%MLTXMoonLake Immunotherapeutics12.05%MTSRMetseraN/AVKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableMLTXMoonLake Immunotherapeutics264.23 million56.49 millionOptionableMTSRMetsera81105.06 millionN/AN/AVKTXViking Therapeutics20112.44 million107.84 millionOptionableCDMO, MLTX, MTSR, and VKTX HeadlinesRecent News About These CompaniesHsbc Holdings PLC Purchases 12,026 Shares of Viking Therapeutics, Inc. $VKTX2 hours ago | marketbeat.comBraidwell LP Trims Position in Viking Therapeutics, Inc. $VKTXSeptember 3 at 7:42 AM | marketbeat.comLandscape Capital Management L.L.C. Buys Shares of 10,003 Viking Therapeutics, Inc. $VKTXSeptember 3 at 5:12 AM | marketbeat.comViking Therapeutics Loses 20% in a Month: How to Play the StockSeptember 2 at 11:31 AM | zacks.comApis Capital Advisors LLC Grows Stock Holdings in Viking Therapeutics, Inc. $VKTXSeptember 2 at 9:19 AM | marketbeat.comBrokers Issue Forecasts for VKTX Q3 EarningsSeptember 2 at 2:13 AM | marketbeat.comQ3 Earnings Forecast for VKTX Issued By B. RileySeptember 2 at 2:13 AM | americanbankingnews.comFORA Capital LLC Has $268,000 Stock Holdings in Viking Therapeutics, Inc. $VKTXSeptember 1 at 4:43 AM | marketbeat.comInvesco Ltd. Sells 787,865 Shares of Viking Therapeutics, Inc. $VKTXSeptember 1 at 3:31 AM | marketbeat.comRafferty Asset Management LLC Sells 87,394 Shares of Viking Therapeutics, Inc. $VKTXAugust 31, 2025 | marketbeat.comAlphaQuest LLC Acquires 9,815 Shares of Viking Therapeutics, Inc. $VKTXAugust 31, 2025 | marketbeat.comRaymond James Financial Inc. Buys 28,922 Shares of Viking Therapeutics, Inc. $VKTXAugust 31, 2025 | marketbeat.comViking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key InsightsAugust 29, 2025 | zacks.comViking Therapeutics to Participate at Upcoming Investor ConferencesAugust 28, 2025 | prnewswire.comAffinity Asset Advisors LLC Acquires Shares of 25,000 Viking Therapeutics, Inc. $VKTXAugust 28, 2025 | marketbeat.comViking Therapeutics, Inc. $VKTX Shares Sold by Russell Investments Group Ltd.August 28, 2025 | marketbeat.comNovo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?August 27, 2025 | zacks.comNuveen LLC Buys Shares of 384,379 Viking Therapeutics, Inc. $VKTXAugust 26, 2025 | marketbeat.comShort Report: Viking Therapeutics short interest at 5-year high after VK273 dataAugust 25, 2025 | msn.comViking Therapeutics, Inc. $VKTX Shares Sold by Charles Schwab Investment Management Inc.August 25, 2025 | marketbeat.com2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top AnalystsAugust 24, 2025 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDMO, MLTX, MTSR, and VKTX Company DescriptionsAvid Bioservices NASDAQ:CDMOAvid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.MoonLake Immunotherapeutics NASDAQ:MLTX$59.50 +0.94 (+1.61%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$60.02 +0.52 (+0.88%) As of 09/3/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Metsera NASDAQ:MTSR$35.66 -0.55 (-1.52%) As of 09/3/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Viking Therapeutics NASDAQ:VKTX$26.83 -0.66 (-2.40%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$27.00 +0.17 (+0.63%) As of 05:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
